Serendip innovations

Dear Serendip followers! 🔔 After just a year and a half of existence, we are thrilled to share our 2024 progress and exciting prospects for 2025. Happy reading! 🚀 Company Update With a €2.7 million pre-Seed funding round closed in December 2024 and strong operational anticipation, our team has grown from 3 co-founders to 10 team members. Growth also means more space! We moved from a 31 m² office to a 440 m² facility, including a brand-new 300+ m² R&D lab, set up in record time (~4 months). Huge kudos to our R&D team! 🥳 With these new assets, we are ready to take a key step: advancing our innovative VLP technology—a true “Swiss Army knife” nanoparticle—to optimize the stabilization and delivery of active molecules for our partners. 📈 Project Update In just one year, six collaborations have been launched or are in the process of being finalized, demonstrating growing interest in our platform and its agile production capabilities. 🦠🌱 Among our most ambitious challenges: ✅ Triggering immune responses specifically against tumors (T-cell response) ✅ Preventing viral infections through an effective B-cell response ✅ Providing an alternative to lipid nanoparticles for better RNA molecule stabilization and in vivo delivery 🔬 Our mission? Solving CMC challenges and tailoring each particle to our partners’ therapeutic compound, its mechanism of action, and the desired biological target. Interested or even curious? Let’s discuss your project! A huge thank you to our Business Angels as well as Bpifrance and Région Grand Est for their invaluable trust and support. More updates are coming soon: technical advancements, collaboration details, our first product development, new patents… Stay tuned! 😊 Your dedicated CEO and team of co-founders With the following support: CNRS Innovation Paris Saclay Cancer Cluster (PSCC) MabDesign Network France Biotech BioValley France Quest for change MATWIN

Hello everyone, it's with great pleasure that I'm starting my first day of a thesis in immunology, whose objective is to develop an immunization system based on particles derived from a phytovirus. 👩🏻🔬 This CIFRE thesis will be carried out within the Institut de biologie moléculaire et cellulaire (IBMC -CNRS) in Strasbourg and the start-up Serendip innovations. I would like to thank my thesis supervisor Dr.Hélène Dumortier and my thesis co-supervisor Dr.Vianney Poignavent for their confidence in me. I wish us all the best for this exciting research project! I would also like to thank Armelle Guingand for providing me with the knowledge I needed during this 4-month training to carry out the rest of your research in the best possible way.

🎉𝗙𝗲́𝗹𝗶𝗰𝗶𝘁𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝘂𝘅 𝟭𝟲 𝗽𝗼𝗿𝘁𝗲𝘂𝗿𝘀 𝗱𝗲 𝗽𝗿𝗼𝗷𝗲𝘁𝘀 𝗽𝗿𝗲́𝘀𝗲́𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝗻𝗲́𝘀 𝗽𝗼𝘂𝗿 𝗿𝗲𝗷𝗼𝗶𝗻𝗱𝗿𝗲 𝗹𝗲 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗲 𝗮𝗰𝗰𝗲𝗹𝗲́𝗿𝗮𝘁𝗲𝘂𝗿 𝗦𝗧𝗔𝗥𝗧 𝗱𝗲 𝗠𝗔𝗧𝗪𝗜𝗡 !🚀 Le programme START accompagne des projets innovants en oncologie à fort potentiel, en leur offrant un soutien stratégique unique sur 6 mois pour accélérer leur développement. Grâce à une expertise scientifique et industrielle de haut niveau, ces projets bénéficient d'un véritable tremplin pour transformer leurs innovations en solutions concrètes pour les patients. 👏 Merci à tous les candidats pour leur participation et bravo aux lauréats ! Ces 16 projets prometteurs illustrent l'excellence de la recherche en oncologie et témoignent de la dynamique collaborative portée par MATWIN à l’échelle européenne ! Nous avons hâte de débuter cette aventure et de contribuer à l'accélération de ces innovations médicales essentielles. Bienvenue 🔹 aubin Penna Université de Poitiers 🔹Nataliya Yeremenko Nantes Université 🔹Dominique HEYMANN Sylvia Colliec-Jouault Nantes Université Institut de Cancérologie de l'Ouest (ICO) Ifremer SATT Ouest Valorisation 🔹Laurent Fontaine Anne-Caroline CHANY Le Mans Université 🔹Michal Tichý IOCB Prague - Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences 🔹Bert M. Klebl Lead Discovery Center GmbH 🔹Coralie Dorard Actipulse Neuroscience® 🔹Jonathan Naccache, PhD Brink Therapeutics 🔹Anne Lecadieu Cure51 🔹Isabel Marey-Semper Doxanano 🔹Rémi Rosière InhaTarget Therapeutics 🔹Cyril GILBERT Kimialys 🔹Hedi Ben Brahim One Biosciences 🔹Marie Schiltz Proskope 🔹Mathilde Coustets see2cure 🔹Alexandre Hill Serendip innovations    👉 Pour en savoir plus sur le programme d’accompagnement MATWIN Unicancer, rendez-vous ici : https://lnkd.in/deuB9vc #Innovation #Oncologie #Startups #MATWIN #Accélérateur #Recherche #Santé

🎉Congrats to the 16 projects preselected to join & enjoy the MATWIN 𝗦𝗧𝗔𝗥𝗧 Acceleration program!🚀 The START program supports innovative oncology projects with high potential, offering them unique strategic support over 6 months to accelerate their development. Thanks to high-level scientific and industrial expertise, these projects benefit from a real springboard to transform their innovations into concrete solutions for patients. 👏 Many thanks to all applicants for their participation, and congratulations to the winners! These 16 promising projects illustrate the excellence of oncology research, and testify to MATWIN's ability to drive a collaborative dynamic on cancer innovation on a European scale! Let's accelerate these medical innovations against #cancer ! Welcome  🔹aubin Penna Université de Poitiers 🔹Nataliya Yeremenko Nantes Université 🔹Dominique HEYMANN Sylvia Colliec-Jouault Nantes Université Institut de Cancérologie de l'Ouest (ICO) Ifremer SATT Ouest Valorisation 🔹Laurent Fontaine Anne-Caroline CHANY Le Mans Université 🔹@Michal Tichý  IOCB Prague - Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences 🔹Bert M. Klebl Lead Discovery Center GmbH 🔹Coralie Dorard Actipulse Neuroscience® 🔹Jonathan Naccache, PhD Brink Therapeutics 🔹Anne Lecadieu Elisabeth Auzias Nicolas Wolikow Cure51 🔹Isabel Marey-Semper Doxanano 🔹Rémi Rosière Frédéric De Coninck InhaTarget Therapeutics 🔹Cyril GILBERT Kimialys 🔹Hedi Ben Brahim One Biosciences 🔹Marie Schiltz Proskope 🔹Mathilde Coustets see2cure 🔹Alexandre Hill Serendip innovations 👉 To learn more about the MATWIN program : https://lnkd.in/gCzFDeF #Innovation #Oncology #Startup #MATWIN #cancer #health Unicancer

https://lnkd.in/eQMfDt84 En attendant une prochaine communication officielle sur les belles et nombreuses avancées de Serendip, OncoSTART parle de nous. 😊 (Merci #Matwin) Coordonné par l’accélérateur MATWIN, le consortium OncoSTART regroupe aujourd’hui un réseau de 14 acteurs clefs engagés dans la recherche et l’innovation contre les cancers, qui assemblent leurs forces pour promouvoir et soutenir l'entrepreneuriat français en oncologie. A très vite pour le prochain update Alexandre Hill Paris Saclay Cancer Cluster (PSCC) MATWIN Cancéropôle Est Unicancer

Serendip innovations is selected to pitch at the Merck's EMEA advance biotech grant program. Stay tuned and connect with us

Nous recrutons un(e) technicien(ne) de laboratoire. #recrutons (#hiring) Vous êtes à la recherche d'un emploi dans une start-up dynamique et vous souhaitez avoir de l'impact au travers d'un projet innovant dans le secteur de l'oncologie. Contactez-nous pour déposer votre candidature!

Nous recrutons un(e) technicien(ne) de laboratoire. #recrutons (#hiring) Vous êtes à la recherche d'un emploi dans une start-up dynamique et vous souhaitez avoir de l'impact au travers d'un projet innovant dans le secteur de l'oncologie. Contactez-nous pour déposer votre candidature!

Could plants be used to grow our medications? #UofG researcher Dr. Jennifer Geddes-McAlister, believes that there is no reason plants should not be making our drugs right now. “The promise is there. The setup and infrastructure are there. The research is there. The biggest hurdle is reducing variability in drug production.” College of Biological Science at the University of Guelph Learn more: https://uoguel.ph/9gvs4

🥳 Gustave Roussy célèbre la recherche clinique lors d’une semaine spéciale. Premier centre européen de lutte contre le #cancer, l'institut est fortement engagé dans le domaine de la recherche clinique. Découvrez en images, la vaccination thérapeutique pour lutter contre le #cancer ⤵ Plus d'informations sur la Semaine de la Recherche Clinique : https://lnkd.in/d47_2QjT